Literature DB >> 27317530

Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris.

Kory Schrom1, Terri Nagy2, Eliot Mostow3.   

Abstract

Isotretinoin is used to treat severe and recalcitrant acne. Possible side effects include depression, suicide, and suicidal ideation; however, other studies suggest isotretinoin may improve mood and quality of life. Although iPLEDGE consenting warns about the risk of depression and suicidal ideation, there is no recommendation for screening tools. The patient health questionnaire-2 and the patient health questionnaire-9 are validated instruments that enable dermatologists to efficiently screen for depression before and after isotretinoin is initiated.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  depression; iPLEDGE; isotretinoin; patient health questionnaire-2; patient health questionnaire-9; screening; suicidal ideation

Mesh:

Substances:

Year:  2016        PMID: 27317530     DOI: 10.1016/j.jaad.2016.02.1148

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Dermatologic Conditions and Risk of Suicide: A Case-Control Study.

Authors:  Deepak Prabhakar; Edward L Peterson; Yong Hu; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; L Keoki Williams; Arne Beck; Gregory E Simon; Brian K Ahmedani
Journal:  Psychosomatics       Date:  2017-08-04       Impact factor: 2.386

Review 2.  Acne and the Lesbian, Gay, Bisexual, or Transgender Teenager.

Authors:  Laura Ragmanauskaite; Benjamin Kahn; BaoChau Ly; Howa Yeung
Journal:  Dermatol Clin       Date:  2019-11-26       Impact factor: 3.478

Review 3.  Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes.

Authors:  Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Maciej Żaczek; Ryszard Międzybrodzki; Sławomir Letkiewicz; Marzanna Łusiak-Szelchowska; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-02-08       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.